PT - JOURNAL ARTICLE ED - , TI - SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors AID - 10.1158/2159-8290.CD-RW2018-043 DP - 2018 May 01 TA - Cancer Discovery PG - OF10--OF10 VI - 8 IP - 5 4099 - http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.short 4100 - http://cancerdiscovery.aacrjournals.org/content/8/5/OF10.full SO - Cancer Discov2018 May 01; 8 AB - Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.